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Abstract: A new simplified, epoxide-free epothilone analog was prepared incorporating an
N-(2-hydroxyethyl)-benzimidazole side chain, which binds to microtubules with high affinity and
inhibits cancer cell growth in vitro with nM potency. Building on this scaffold, a disulfide-linked
conjugate with the purported EGFR-binding (EGFR, epidermal growth factor receptor) peptide GE11
was then prepared. The conjugate retained significant microtubule-binding affinity, in spite of the
size of the peptide attached to the benzimidazole side chain. The antiproliferative activity of the
conjugate was significantly lower than for the parent scaffold and, surprisingly, was independent of
the EGFR expression status of cells. Our data indicate that the disulfide-based conjugation with the
GE11 peptide is not a viable approach for effective tumor-targeting of highly potent epothilones and
probably not for other cytotoxics.
Keywords: cancer; drug discovery; epothilone; medicinal chemistry; microtubule-stabilizing agents;
prodrug; total synthesis; tumor-targeting
1. Introduction
Tubulin modulators represent an important class of anticancer drugs that includes
microtubule-stabilizing agents (MSA) such as paclitaxel, docetaxel, and ixabepilone as well as
microtubule disrupters such as vinblastine and vincristine [1]. However, in spite of their clinical
relevance and therapeutic success, drugs acting on the tubulin/microtubule system are still associated
with significant side effects, due to the ubiquitous nature of their target protein tubulin [2].
Thus, the specific targeting of tubulin modulators, and cytotoxic agents in general, to tumors, has
emerged as an important strategy in anticancer drug discovery and development. The most advanced
approach towards the tumor-targeting of cytotoxic agents is their attachment to tumor-specific
antibodies, with three antibody-drug conjugates (ADCs) being currently approved for cancer treatment
in humans [3,4]; for two of these ADCs, the cytotoxic payload is a microtubule disrupter, i.e.,
monomethyl auristatin for brentuximab vedotin and the maytansine derivative DM-1 for trastuzumab
emtansine. Alternative targeting moieties are peptides [5] or small molecules that interact specifically
with proteins on tumor cell surfaces (e.g., folic acid [6] or synthetic organic molecules [7,8]).
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When designing tumor-targeted conjugates of cytotoxic agents, two of the most crucial questions
relate to the site of the attachment of the linker between the bioactive parent molecule and the targeting
moiety and the nature of the linker moiety itself. Numerous linker modalities have been investigated
in the literature, including protease/peptidase-cleavable linkers or simple disulfide groups (often
in combination with a self-immolative structural element) [9]. Interestingly, the approved ADC
trastuzumab emtansine incorporates a non-cleavable linker and the release of the active drug moiety is
based on lysosomal degradation of the targeting antibody, leaving behind a construct composed of
DM-1, the connector between DM-1 and the antibody, and the lysine reside to which the connector
is attached as the pharmacologically active agent. We have recently shown for the first time that
this construct does indeed bind to tubulin with similar affinity as the parent compound DM-1 (as its
methylsulfanyl derivative) [10].
Epothilones A and B (Epo A and B) (Figure 1) are 16-membered myxobacterial macrolides that
exhibit potent microtubule-stabilizing activity [11,12]. Both compounds exert strong antiproliferative
effects on human cancer cells in vitro [12,13] and in human xenograft models in mice, including cell
lines and tumors with taxol resistance [14–16]. The cytotoxic activity of Epo A is similar to that of
taxol, whereas Epo B is generally more potent than taxol by at least one order of magnitude, with
sub-nanomolar IC50 values for most cell lines [12,13].
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Epothilones have been the subject of extensive SAR studies and at least eight epothilone-type 
agents have been advanced to clinical trials in humans in cancer [17,18], including the FDA-approved 
anticancer drug ixabepilone (the lactam analog of Epo B) [19]; in addition, 12,13-deoxy-Epo B (Epo 
D) has been investigated in Phase I clinical trials for Alzheimer’s disease [20]. While development of 
most of these compounds has been terminated (including the development of Epo D for Alzheimer’s 
disease), an analog termed utidelone (or UTD1) is currently undergoing Phase III clinical studies for 
breast cancer treatment in combination with capecitabine [21]. (Very surprisingly (and, in fact, 
irritatingly), several publications on this compound have appeared in the peer-reviewed literature, 
without its structure being revealed in any of these papers) [22]. Known attempts at the development 
of tumor-targeted derivatives of epothilones so far have been limited to the highly elaborate folate 
conjugate BMS-753493 (epofolate) (Figure 1) [23], where linker cleavage involves intracellular 
disulfide reduction followed by intramolecular ester cleavage to produce an N-(2-hydroxyethyl) 
derivative of aziridine-Epo A as the cytotoxic effector molecule. 
In this paper, we report a different approach towards the design of epothilone-based tumor-
targeted conjugates that is based on the benzimidazole-containing, structurally simplified 
cyclopropyl-trans-epothilone A analog 1 (Figure 2). We have previously shown that the related 
epothilone analog 3 (Figure 2) shows similar antiproliferative activity as Epo B [24]; at the same time, 
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BMS-753493 (epofolate).
Epothilones have been the subject of extensive SAR studies and at least eight epothilone-type
agents have been advanced to clinical trials in humans in cancer [17,18], including the FDA-approved
anticancer drug ixabepilone (the lactam analog of Epo B) [19]; in addition, 12,13-deoxy-Epo B (Epo
D) has been investigated in Phase I clinical trials for Alzheimer’s disease [20]. While development of
most of these compounds has been terminated (including the development of Epo D for Alzheimer’s
disease), an analog termed utidelone (or UTD1) is currently undergoing Phase III clinical studies
for breast cancer treatment in combination with capecitabine [21]. (Very surprisingly (and, in fact,
irritatingly), several publications on this compound have appeared in the peer-reviewed literature,
without its structure being revealed in any of these papers) [22]. Known attempts at the development
of tumor-targeted derivatives of epothilones so far have been limited to the highly elaborate folate
conjugate BMS-753493 (epofolate) (Figure 1) [23], where linker cleavage involves intracellular disulfide
reduction followed by intramolecular ester cleavage to produce an N-(2-hydroxyethyl) derivative of
aziridine-E o A as the cytotoxic effector molecule.
In this paper, we report a different appro ch towards the design of epoth lone-based
tum r-targeted c njugates that is based on the benzimidazole-containing, struc urally simplified
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cyclopropyl-trans-epothilone A analog 1 (Figure 2). We have previously shown that the related
epothilone analog 3 (Figure 2) shows similar antiproliferative activity as Epo B [24]; at the same time,
the presence of the larger 2-hydroxyethyl substituent on the benzimidazole moiety was found to
be well tolerated for a corresponding cyclopropyl-Epo B derivative [25]. Lastly, the replacement of
the epoxide moiety in natural epothilones by a cyclopropane ring is expected to lead to enhanced
metabolic stability.
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Figure 2. Molecular structures of epothilone analogs 1–3 and of the tumor-targeted epothilone peptide
conjugate 4.
In the actual tumor-targeted conjugate 4, the thiol analog of 1 (i.e., 2) is connected to the side chain
of a Cys residue added to the N-terminus of the epidermal growth factor receptor (EGFR)-binding
peptide GE11 [26]. Reductive disulfide cleavage of this conjugate, thus, would directly lead to the
cytotoxic effector molecule without the need for a subsequent immolative step (as in BMS-753493).
The EGFR (HER1, ErbB1) is a 170 kDa transmembrane glycoprotein with an intracellular tyrosine
kinase effector domain [27]. Enhanced EGFR signaling is associated with increased proliferation,
differentiation, angiogenesis, invasion and metastasis and overexpression or mutation of EGFR is
characteristic of a variety of human tumors [28]. Importantly in the context of this work, the EGFR
is the targeted cell surface element for one of the marketed ADCs (trastuzumab emtansine). GE11
is a 12-amino acid residue peptide of the sequence YHWYGYTPQNVI, which has been reported to
bind to EGFR with high affinity and specificity (Kd 22 nM), to be internalized preferentially into
cells with high EGFR expression levels and to accumulate in EGFR-overexpressing tumor xenografts
after i.v. administration in vivo [26]. GE11 has been investigated as a tumor-targeting device, e.g.,
in liposomes [29], nanoparticles [30], or olymeric prodrugs [31], but also for recept r imaging
purposes [32].
2. Results and Discussion
2.1. Chemistry
The synthesis of both epothilone analog 1 as well as GE11-conjuagte 4 proceeded through the
prot cted macrolactone 12 as a key precursor; as outlined in Scheme 1, the latter was obtained from the
known olefin 5 [25] as an advanced inter ediate. 1,4-diol
gave allylic alcohol 6 as an inseparable ca. 3:1 mixture of E/Z isomers, which was sub itte as such
to Charette cyclopropanation [33]. The cyclopr anation reaction furnished a mixture of products
7 that could not be separated. According to 1 - , t o major isomers were prese t in a ca.
9:1 ratio, but it as not deter ined if these isomers were distinguished by the configuration of the
hydroxyl-bearing stereocenter (as a consequence of the imperfect stereochemical purity of olefin 5)
or by the stereochemistry of the cyclopropane moiety. Oxidation of 7 with Dess–Martin periodinane
furnished aldehyde 8 as a mixture of three detectable isomers in a 1:0.14:0.03 ratio (based on the
aldehyde signal in the 1H-NMR spectrum), which again proved to be inseparable. Aldehyde 8 was
obtained in a 58% overall yield for the three-step sequence from olefin 5.
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Scheme 1. (a) cis-But-2-ene-1,4-diol, Hoveyda-Grubbs II (20 mol %), DCM, rt, 22
h, 80%, E/Z ca. 3:1. (b) i. Et2Zn, CH2I2, DCM, −10 ◦C, 15 min; ii. 6,
(4S,5S)-2-butyl-N,N,N’,N’-tetramethyl-1,3,2-dioxaborolane-4,5-dicarboxamide, DCM, 0 ◦C to rt, 2h,
78%. (c) DMP, DCM, rt, 5 h, 92%. (d) LiHMDS, THF, −78 ◦C to rt, 2 h, 72%. (e) NBSH, TEA, DCM, rt,
16 h, 98%. (f) CSA, DCM/MeOH 1:1, rt, 16 h, quant. (g) LiOH, t-BuOH/H2O 4:1, rt, 2.5 h, 98%. (h) 2,4,6
trichlorobenzoyl chloride, DMAP, TEA, toluene, rt, 2 h, 51%. Abbreviations: DCM: dichloromethane;
DMP: Dess–Martin periodinane; CSA: camphorsulfonic acid; DMAP: 4-dimethylaminopyridine;
LiHMDS: lithium hexamethyldisilazane; NBSH: o-nitrobenzenesulfonylhydrazide; TEA: triethylamine;
THF: tetrahydrofuran.
The elaboration of aldehyde 8 into the epothilone macrocyclic framework in a first step entailed
Julia–Kocienski olefination with sulfone 9 (Scheme 1) [34]. The reaction was best carried out under
Barbier conditions in the presence of two equivalents of LiHMDS, which furnished the desired olefin in
a 72% yield with ca. 2/1 selectivity (based on 1H-NMR). The low selectivity of the olefination reaction
was inconsequential, as the double bond was reduced in the next step with diimide to provide the
fully protected seco ester 10 in quantitative yield. Either 2,4,6-triisopropylbenzenesulfonylhydrazide
(TPSH) [35] or o-nitrobenzenesulfonylhydrazide (NBSH, as a cheaper alternative) [36] could be
employed as a diimide source, with both methods delivering 10 in excellent yields. Selective cleavage
of the benzylic silyl-ether with CSA in DCM/MeOH 1:1 then furnished alcohol 11 in quantitative
yield. (Careful inspection of the NMR spectra of 10 and 11 suggested the presence of at least one minor
isomer in both cases, whose content was difficult to quantify, however). Saponification of methyl ester
11 gave a crude acid that was directly submitted to Yamaguchi macrolactonization [37], to give the
fully protected macrolactone 12 in 51% yield after purification by preparative RP-HPLC. Ca. 500 mg
of this key intermediate were prepared in a purity that was sufficient for subsequent manipulations,
thus highlighting the practicability of the process developed.
As illustrated in Scheme 2, global deprotection of 12 with HF·pyridine gave trans-cyclopropyl
epothilone 1 in 33% yield after purification by preparative RP-HPLC. Alternatively, 12 could be
selectively deprotected at the primary hydroxyl group with TASF (tris(dimethylamino)sulfonium
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difluoromethylsilicate) [38] to give the partially protected macrolactone 13 in quantitative yield.
Mitsunobu reaction with thioacetic acid as the nucleophile then gave a thioester derivative from
which the O-TIPS (triisopropylsilylether) protecting group was removed with HF·pyridine, to provide
thioacetate 14. The latter could be directly converted into the activated mixed disulfide 15 by reaction
with 2,2′-dipyridyl disulfide under slightly basic conditions. Reaction of 15 with CysGE11 then
provided the desired epothilone-GE11 conjugate 4.
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elution of the material from the HPLC column and lyophilization of the sample. Only disulfide 16 
could be isolated and characterized. 
2.2. Biological Assessment 
In order to provide a rational framework for the biological assessment of the epothilone peptide 
conjugate 4, EGFR was quantified in cell lines that were to be used for those experiments, i.e., A431 
epidermoid squamous cell carcinoma cells, SW480 colorectal adenocarcinoma cells, and HEK293 
embryonic kidney cells. A431 cells have been reported to highly overexpress EGFR [39]; consistent 
overexpression of EGFR has also been described for SW480 cells [40]. In contrast, HEK293 cells were 
previously found not to express EGFR [39]. Expression levels of EGFR were assessed by the treatment 
of cells with cetuximab followed by FACS-based quantification of cetuximab with an Alexa Fluor 647 
Scheme 2. (a) HF·py, MeCN, rt, 16 h, 33% after HPLC. (b) TASF, DMF, 0 ◦C, 2 h, quant. (c) PPh3,
DEAD, AcSH, Et2O, 0 ◦C to rt, 3.5 h. (d) HF·py, pyridine, MeCN, rt, 53 h, 87% (2 steps). (e)
2,2′-dipyridyl disulfide, K2CO3, MeOH, rt, 30 min, 79%. (f) CysGE11, MeOH, rt, 2 h, 15% after HPLC.
(g) K2CO3, MeOH, rt, 20 min, 24% after RP-HPLC. Abbreviations: TASF: tris(dimethylamino)sulfonium
difluoromethylsilicate; DMF: dimethyl formamide; DEAD: diethyl azodicarboxylate.
While the thioester moiety of 14 could be readily cleaved with K2CO3/MeOH, the resulting free
thiol 2 could not be isolated as a pure material. Disulfide formation was already observed between
elution of the material from the HPLC column and lyophilization of the sample. Only disulfide 16
could be isolated and characterized.
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2.2. Biological Assessment
In order to provide a rational framework for the biological assessment of the epothilone peptide
conjugate 4, EGFR was quantified in cell lines that were to be used for those experiments, i.e., A431
epidermoid squamous cell carcinoma cells, SW480 colorectal adenocarcinoma cells, and HEK293
embryonic kidney cells. A431 cells have been reported to highly overexpress EGFR [39]; consistent
overexpression of EGFR has also been described for SW480 cells [40]. In contrast, HEK293 cells were
previously found not to express EGFR [39]. Expression levels of EGFR were assessed by the treatment
of cells with cetuximab followed by FACS-based quantification of cetuximab with an Alexa Fluor
647 goat anti-human antibody. In line with the existing literature, EGFR expression levels were found
to be highest in A431 cells, followed by SW480 cells. HEK293 cells gave fluorescence intensities at the
level of the isotype control (Figure S1). Therefore, 4 would have been expected to display strongest
cytotoxicity against A431 and SW480 cells, while HEK293 cells should have been largely insensitive to
the action of the conjugate. As will be discussed below, the experimental results did not conform to
these predictions.
The stability of the epothilone-GE11 conjugate 4 in complete cell culture medium was evaluated
under conditions resembling those encountered in the cytotoxicity assays. Thus, an 8.6 µM solution of
4 in RPMI with 10% FBS was incubated for 3 days at 37 ◦C and subsequently analyzed by RP-HPLC.
Only minor degradation of 4 (<10%) was observed under these conditions (data not shown).
The reductive cleavage of conjugate 4 was analyzed under conditions mimicking those found
in the endosome and the cytoplasm of cancer cells [41]. Endosome-like conditions were assumed to
be reproduced by a 10 mM solution of glutathione (GSH) in acetate and phosphate buffer pH 4.9;
cytoplasm-like conditions entailed 10 mM GSH in phosphate buffer pH 7.4. Under both conditions,
rapid disappearance of 4 was observed with apparent first order kinetics (Figure 3).
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Figure 3. Kinetics of glutathione (GSH)-mediated reduction of epothilone-peptide conjugate 4 (173 µM
4, 10 mM GSH, pH 4.9 (endosome-like conditions), triangles, or pH 7.4 (cytoplasm-like conditions),
circles). Conjugate 4 was added to the respective GSH solutions as a solution in phosphate buffer pH
7.4 at room temperature, to reach a total concentration of 173 µM. Samples were quenched at different
time points with 10% metaphosphoric acid and analyzed by RP-HPLC. The peak areas for 4 in the
RP-HPLC chromatograms were normalized against the peak area of a 200 µM solution of 4 in the
corresponding GSH-free buffers.
The half-life of 4 was 1.1 min under endosome-like conditions, while no residual conjugate was
detectable even 1 min after addition to the glutathione solution under cytoplasm-like conditions
(estimated half-life of ca. 0.2 min). LC/MS analysis of cleavage solutions showed that the products
obtained at both pH values included the mono- and dimeric CysGE11 peptide, thiol-containing
epothilone analog 2, the mixed disulfide of 2 with glutathione, and dimer 16. The mixed disulfide
of 2 with glutathione appeared very early in the reaction (Figure S2); it was later transformed into 2
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and 16. The shorter half-life of 4 under cytoplasm-like conditions is in line with the fact that disulfide
reduction is pH-dependent and has been shown to be significantly slower at lower pH [41].
The binding affinity of epothilone analogs 1, 14, and 16 and of targeted conjugate 4
for microtubules was determined as previously described by Díaz and co-workers, using
partly cross-linked microtubules and determining the changes in fluorescence anisotropy upon
displacement of the fluorescent taxol derivative Flutax-2 [42,43] (Figure S3). Not unexpectedly,
the microtubule-binding affinity of the simplified epothilone analog 1 even exceeds that of natural
Epo A (Kb of 7.85 × 107 M−1 vs. 3.17 × 107 M−1 for Epo A; Table 1); this observation is in line with
existing SAR data for other epothilone analogs that are derived from trans-Epo A and/or incorporate a
benzimidazole side chain [24,25,44], although analog 1 has not been investigated previously. Compared
to 1, the Kb for thioacetate 14 is considerably lower (>10-fold), but its microtubule-binding affinity
is still comparable to that of other epothilone analogs that have shown nanomolar antiproliferative
activity against different cancer cell lines [45]. Intriguingly, analog 16 and conjugate 4 exhibit similar
microtubule-binding affinity as thioacetate 14, in spite of the significant enlargement in size of the
substituent group on the benzimidazole side chain. Importantly, the targeting peptide CysCE11
showed no relevant microtubule binding.
Table 1. Binding constants of epothilone analogs 1, 14, and 16 and of epothilone-CE11 conjugate 4 for
stabilized microtubules 1.
Compound Kb [106 M−1]
1 78.5 ± 17.2
14 5.4 ± 0.8
16 9.8 ± 0.3
4 9.3 ± 0.5
CysCE11 0.05 ± 0.02
Epo A 31.7 ± 3.1
Docetaxel 26.7 ± 3.3
1 Association constant Kb with glutaraldehyde-stabilized microtubules at 35 ◦C, determined as described in [42].
Numbers are average values from 3 independent experiments ± standard deviation.
The antiproliferative activity of the targeted epothilone conjugate 4 was assessed for A431,
SW480, and HEK293 cells, in comparison with epothilone analogs 1 and 16. Of the three compounds
investigated, conjugate 4 proved to be the least potent by one order of magnitude (Table 2).
Table 2. Antiproliferative activity of epothilone analogs 1 and 16 and of epothilone-CE11 conjugate 4
against human cancer cell lines (IC50 [nM]) 1.
Compound A431 SW480 HEK293
1 3.32 ± 0.60 17.56 ± 3.50 0.87 ± 0.13
16 8.37 ± 0.81 8.91 ± 1.26 2.08 ± 0.53
4 74.74 ± 6.65 180.8 ± 25.9 31.09 ± 6.21
Epo A 2.94 ± 0.30 14.52 ± 1.09 2.71 ± 0.62
1 Cells were incubated with test compounds for 72 h. A431: epidermoid squamous cell carcinoma cells; SW480:
colorectal adenocarcinoma cells; HEK293: embryonic kidney cells. Numbers presented are average values from
three independent experiments ± standard deviation. For experimental details see the Supplementary Materials.
While the lower activity of 4 compared to 1 against A431 and SW480 cells could potentially be
rationalized by a lower rate of receptor-mediated uptake vs. uptake by passive diffusion (which is
likely to be operative for 1) and/or the efficiency of formation of 2 from 4 in, and its release from,
the endosomal compartment, the lack of selectivity between EGFR-expressing A431 and SW480 cells
and essentially EGFR-free HEK293 cells is difficult to explain. This finding may point to cleavage of
the disulfide bond in the extracellular space, and the passive diffusion of 2 into the cells (assuming
that passive diffusion of conjugate 4 through the cell membrane followed by intracellular disulfide
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reduction is essentially excluded). Should this indeed be the case, the same mechanism may also
underlie the activity of 4 against A431 and SW480 cells, without the involvement of EGFR-mediated
endocytosis. In this context, it should be remembered that 10% disulfide cleavage or less would already
account for the observed IC50 values, if one assumes the (elusive) epothilone 2 to exhibit similar activity
as 1. Extracellular disulfide cleavage as the source of the antiproliferative activity of 4 would thus still
be compatible with the stability data obtained for the compound in cell culture medium (vide supra).
Preliminary experiments aiming at the quantification of intracellular concentrations of 4, 2, or 16 did
not produce any interpretable results.
In a broader context, we note that recycling endosomes, late endosomes, and lysosomes, in
contrast to our own basic assumption, had been suggested to provide a reducing, rather than oxidizing
environment, even prior to the start of our work on 4 [46]. At the same time, careful inspection
of the literature suggests that, while the GE11 peptide does seem to allow selective targeting of
EGFR-overexpressing cells by nanoparticles [30] or polymeric prodrugs [31], the selectivity that has
been achieved is rather moderate. In line with these observations, the reported Kd of 22 nM of GE11
for the EGFR could not be reproduced in subsequent studies by other laboratories. Thus, Levitzki
and co-workers determined the IC50 for the displacement of [125I]-EGF from the EGFR by GE11 to be
>1 mM (!) (vs. 5.1 nM for EGF) [47]; more recently, Lin and co-workers determined the Kd of GE11
for the EGFR as 459 µM by means of surface plasmon resonance [48]. Similar findings have been
reported by Sihver and co-workers in the context of studies on potential GE11-derived PET imaging
agents [49]. Thus, in retrospect, neither the choice of the GE11 peptide as an EGFR-targeting moiety
nor its combination with a disulfide linker may have been optimal.
The antiproliferative activity of disulfide 16 is similar to that of analog 1, in spite of its >10-fold
lower microtubule-binding affinity. While microtubule-binding affinity is not necessarily linearly
correlated with cell growth inhibition, this finding may point to thiol-containing epothilone analog 2 as
the species mainly responsible for the antiproliferative effects of 16. It is easily conceivable for disulfide
16 to readily cross the cellular membrane by passive diffusion (the molecular weight of 16 is 1054 vs.,
e.g., 856 for taxol, which easily enters cells); immediate reduction in the cytoplasmic compartment
would then produce 2. However, we do not have any experimental data at this point to support this
(plausible) mechanistic hypothesis.
3. Materials and Methods
3.1. Chemistry
All non-aqueous reactions were carried out under anhydrous conditions and under an argon
atmosphere unless otherwise noted. CH2Cl2 was distilled from CaH; THF, Et2O, benzene, and toluene
were distilled from Na/benzophenone. All other absolute solvents were purchased from Fluka
(absolute over molecular sieves). Commercial chemicals were used without further purification, unless
otherwise noted.
Solvents for extractions, column chromatography, and thin layer chromatography (TLC) were
purchased as commercial grade and distilled prior to use. TLC was performed on Merck TLC
aluminum sheets (silica gel 60, F254). Spots were visualized with UV light (254 nm) or through
staining with an aqueous solution of phosphomolybdic acid, cerium sulfate, and sulfuric acid (CPS).
Chromatographic purification of products was performed by flash chromatography (FC) using Fluka
silica gel 60 for preparative column chromatography (particle size 40–63 µm). Organic solutions were
concentrated by rotary evaporation at 40 ◦C and approximately 20 mbar. The compounds were further
dried under high vacuum (0.01–0.001 mbar). Yields refer to compounds isolated after FC, unless
otherwise specified. NMR spectra were recorded on a Bruker AV-400 400 MHz or a Bruker AV-500
500 MHz NMR spectrometer (Bruker Biospin AG, Fällanden, Switzerland) at 298 K. NMR spectra are
referenced relative to the residual hydrogen signal of the deuterated solvent (1H 7.26 ppm, 13C 77.0
ppm for CDCl3). All 13C spectra were measured with complete proton decoupling. For inseparable
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diastereomeric mixtures, only signals of the major diastereomer are reported. Spin multiplicities are
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet,
m = multiplet, mc = centered multiplet, br = broad signal; J = coupling constant in Hz. Infrared spectra
(IR) were recorded on a Jasco FT/IR-6200 instrument. Positions of absorption bands are given in
wavenumbers [cm−1]. Optical rotations were measured on a Jasco P-1020 polarimeter and are reported
as follows: [α]24D : concentration (g/100 mL) and solvent. High resolution mass spectra (HRMS) were
recorded by the ETH Zürich MS service on a Varian IonSpec Ultima (ESI) or a Waters Micromass
Autospec Ultima spectrometer (EI). RP-HPLC was carried out on a Merck Hitachi device (column oven
L-2350, diode array detector L-2450, autosampler L-2200, pump L-2130) using a Waters Symmetry C18
column, 3.5 µm, 4.6 × 100 mm, at a flow rate of 1 mL/min for analytical purposes; a Waters Symmetry
C18 column, 5 µm, 7.8 × 100 mm, at a flow rate of 2 mL/min was employed for semi-preparative
applications. The column temperature for analytical and semi-preparative applications was 40 ◦C.
Preparative RP-HPLC was carried out on a Gilson device (Gilson (Schweiz) AG, Mettmenstetten,
Switzerland) with a Waters Symmetry C18 column (Waters AG, Baden-Dättwil, Switzerland), 5 µm, 19
× 100 mm, at a flow rate of 25 mL/min at room temperature. Peaks were detected at 280, 254, or 220
nm. The Cys-GE11 peptide was custom-made by Biosyntan GmbH (Berlin, Germany).
(S,E)-5-((tert-Butyldimethylsilyl)oxy)-5-(1-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-2-methyl
-1H-benzo[d]imidazol-5-yl)pent-2-en-1-ol (6)
A solution of Hoveyda-Grubbs II catalyst (104.6 mg, 0.167 mmol) in DCM (0.2 mL) was added
to a solution of olefin 5 (500 mg, 0.835 mmol) and cis-2-butene-1,4 diol (206 µL, 2.504 mmol) in DCM
(6 mL) at rt. The solution was stirred for 22 h at rt. It was then concentrated in vacuo and purified by
FC (EtOAc/MeOH 100:1) to yield 420.2 mg of 6 as a ca. 3/1 mixture of E/Z isomers.
Rf = 0.31 (EtOAc/MeOH 20:1). [α]
20
D = −16.8 (c = 1.1 in CHCl3). 1H NMR (400 MHz, CDCl3):
δ = 7.60 (1H, s), 7.24–7.43 (10H, m), 7.13 (1H, dd, J = 1.43, 8.30 Hz), 7.05 (1H, d, J = 8.30 Hz), 5.65
(2H, m), 4.79 (1H, dd, J = 5.41, 6.95 Hz), 4.22 (2H, t, J = 5.59 Hz), 4.04 (2H, d, J = 4.68 Hz), 3.90 (2H, t,
J = 5.59 Hz), 2.54 (3H, s), 2.37-2.65 (2H, m), 0.93 (9H, s), 0.88 (9H, s), 0.02 (3H, s), −0.14 ppm (3H, s). 13C
NMR (100 MHz, CDCl3): δ = 152.30, 142.38, 139.24, 135.51, 134.53, 132.63, 131.64, 129.95, 129.72, 127.90,
120.25, 116.37, 108.97, 75.43, 63.77, 62.10, 45.88, 44.51, 26.74, 26.00, 19.02, 18.39, 14.09, −4.40, −4.76. IR:
ν = 3245, 2953, 2929, 2857, 2357, 1520, 1471, 1429, 1404, 1360, 1254, 1110, 1085, 1007, 940 835, 776, 739,
702 cm−1. HRMS (ESI): m/z calcd for C37H52N2O3Si2 + H+: 629.3589 [M + H+]; found 629.3589.
((1R,2S)-2-((S)-2-((tert-Butyldimethylsilyl)oxy)-2-(1-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-2
-methyl-1H-benzo[d]imidazol-5-yl)ethyl) cyclopropyl)methanol (7)
Diiodomethane (0.16 mL, 2 mmol) was slowly added to a solution of diethyl zinc (1 M in hexane,
1 mL, 1 mmol) in DCM (1 mL) at −10 ◦C and the solution was stirred for 15 min. (Note the section
about EXPLOSIONS in [33]). A preformed solution of allylic alcohol 6 (97 mg, 0.154 mmol) and
(4S,5S)-2-butyl-N,N,N’,N’-tetramethyl-1,3,2-dioxaborolane-4,5-dicarboxamide (97 µL, 0.386 mmol) in
DCM (3 mL) was added at 0 ◦C. The solution was stirred for 2 h at rt. It was then washed with
1 M HCl, and the aqueous phase was re-extracted with DCM. The organic layers were transferred
to an Erlenmeyer flask, 2 M NaOH and H2O2, 30%, 6:1, were added in one portion, and the mixture
was vigorously stirred for 5 min. The organic layer was then successively washed with 1 M HCl and
sat. aq. Na2SO3, dried over MgSO4 and concentrated in vacuo. Purification of the residue by FC
(EtOAc/MeOH 100:1) yielded 77.7 mg of cyclopropane 7 as a mixture of at least two isomers (see text).
Rf = 0.39 (EtOAc/MeOH 95:5). [α]
20
D = −21.1 (c = 1.1 in CHCl3). 1H NMR (400 MHz, CDCl3):
δ = 7.63 (1H, s), 7.24–7.44 (10H, m), 7.14 (1H, dd, J = 1.39, 8.28 Hz), 7.05 (1H, d, J = 8.28 Hz), 4.84 (1H,
t, J = 6.17 Hz), 4.22 (2H, t, J = 5.68 Hz), 3.89 (2H, t, J = 5.68 Hz), 3.37 (2H, m), 2.54 (3H, s), 1.51–1.81
(2H, m), 0.93 (9H, s),0.89 (9H, s), 0.79 (1H, m), 0.65 (1H, m), 0.30 (2H, m), 0.03 (3H, s), −0.12, (3H, s).
13C NMR (100 MHz, CDCl3): δ = 152.28, 142.41, 139.64, 135.53, 134.49, 132.66, 129.96, 127.91, 120.31,
116.41, 108.94, 75.49, 67.13, 62.13, 45.90, 45.56, 26.75, 26.05, 21.52, 19.04, 18.39, 14.10, 13.92, 9.81, −4.40,
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−4.78 ppm; IR: ν = 3266, 2953, 2929, 2857, 1520, 1471, 1429, 1403, 1360, 1253, 1111, 1086, 939, 836, 776,
739, 703 cm−1. HRMS (ESI): m/z calcd for C38H54N2O3Si2 + H+: 643.3746 [M + H+]; found 643.3744.
(1R,2S)-2-((S)-2-((tert-Butyldimethylsilyl)oxy)-2-(1-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-2
-methyl-1H-benzo[d]imidazol-5-yl)ethyl) cyclopropanecarbaldehyde (8)
DMP (19.8 mg, 0.047 mmol) in DCM (1 mL) was slowly added to a solution of alcohol 7 (30 mg,
0.047 mmol) in DCM (1 mL) and the solution was stirred for 5 h at rt. More DMP (10 mg, 0.024 mmol)
in DCM (1 mL) was added at this point and stirring was continued for 1 h. The reaction mixture was
evaporated and the crude residue was directly purified by FC (EtOAc/MeOH 100:1), to yiel 27.4 mg
aldehyde 8 (92%) as a mixture of 3 isomers in a ratio of 1: 0.14: 0.03.
Rf = 0.73 (EtOAc/MeOH 95:5). [α]
20
D = −28.5 (c = 0.4 in CHCl3). 1H NMR (400 MHz, CDCl3):
δ = 8.87 (1H, d, J = 5.57 Hz), 7.61 (1H, s), 7.25–7.43 (10H, m), 7.11 (1H, dd, J = 1.31, 8.30 Hz), 7.06 (1H, d,
J = 8.30 Hz), 4.85 (1H, dd, J = 5.02, 6.88 Hz), 4.23 (2H, t, J = 5.68 Hz), 3.89 (2H, t, J = 5.68 Hz), 2.54 (3H,
s), 1.93 (1H, m), 1.56 (2H, m), 1.49 (1H, m), 1.20 (1H, m), 0.93 (9H, s), 0.89 (9H, s), 0.85 (1H, m), 0.03 (3H,
s), −0.15 ppm (3H, s). 13C NMR (100 MHz, CDCl3): δ = 201.03, 152.42, 142.31, 139.09, 135.53, 134.64,
132.65, 129.99, 127.93, 120.33, 116.18, 109.11, 75.10, 62.14, 45.94, 44.51, 30.54, 26.76, 26.02, 19.39, 19.05,
18.33, 14.42, 14.05, −4.42, −4.82. IR: ν = 2953, 2928, 2856, 2352, 1708, 1521, 1471, 1463, 1429, 1402, 1361,
1255, 1111, 1086, 937, 836, 778, 745, 736, 703 cm−1. HRMS (ESI): m/z calcd for C39H52N2O3Si2 + H+:
641.3589 [M + H+]; found 641.3592.
(6R,7S,8S,E)-Methyl-11-((1R,2S)-2-((S)-2-((tert-butyldimethylsilyl)oxy)-2-(1-(2-((tert
-butyldiphenyl-silyl)oxy)ethyl)-2-methyl-1H-benzo[d]imidazol-5-yl)ethyl)cyclopropyl)-4,
4,6,8-tetramethyl-5-oxo-7-((triisopropylsilyl)oxy) undec-10-enoate (10A)
A solution of LiHMDS (618 mg, 3.969 mmol) in THF (1 mL) was added to a solution of sulfone
9 [34] (1.07 g, 1.680 mmol) and aldehyde 8 (1.3 g, 2.028 mmol) in THF (5 mL) at −78◦C. The mixture
was stirred for 1 h at −78 ◦C and allowed to warm to rt over a period of 1 h. After quenching the
reaction with sat. aq. NH4Cl, the solution was extracted with EtOAc, and the combined extracts were
dried over MgSO4 and concentrated in vacuo. Purification of the residue by FC (Hex/EtOAc/MeOH
1:1:0.01) yielded 1.4 g of olefin 10A as a mixture of isomers (see text).
Rf = 0.88 (EtOAc/MeOH 20:1). [α]
20
D = −13.3 (c = 0.8 in CHCl3). 1H NMR (400 MHz, CDCl3):
δ = 7.60 (1H, s), 7.24–7.42 (10H, m), 7.10 (1H, m), 7.04 (1H, m), 5.32 (1H, m), 4.95 (1H, m), 4.79 (1H, m),
4.22 (2H, t, J = 5.30 Hz), 4.04 (1H, m), 3.89 (2H, t, J = 5.39 Hz), 3.65 (3H, s), 3.15 (1H, m), 2.54 (3H, s),
2.22 (2H, m), 1.88-2.06 (2H, m), 1.83 (2H, m,), 1.74 (1H, m), 1.47 (1H, m), 1.28 (1H, m), 1.19 (3H, s), 1.10
(28H, m), 0.93 (12H, br s), 0.88 (9H, s), 0.82-0.86 (1H, m), 0.41 (1H, t, J = 6.66 Hz), 0.03 (3H, s), −0.15
(3H, s). 13C NMR (100 MHz, CDCl3): δ = 217.98, 174.14, 152.20, 142.55, 140.00, 135.54, 135.06, 134.48,
132.67, 129.96, 127.92, 126.34, 120.43, 116.35, 108.77, 77.32, 75.66, 62.14, 51.77, 47.70, 46.28, 45.91, 43.42,
40.23, 35.12, 34.44, 29.89, 26.76, 26.07, 24.80, 21.56, 19.04, 18.61, 18.59, 18.38, 17.83, 16.68, 16.45, 15.97,
14.15, 13.66, −4.38, −4.76. IR: ν = 2926, 2856, 2362, 1741, 1697, 1521, 1462, 1430, 1389, 1360, 1254, 1112,
1087, 883, 836, 702 cm−1; HRMS (ESI): m/z calcd for C62H98N2O6Si3 + H+: 1051.6805 [M + H+]; found
1051.6796.
(6R,7S,8S)-Methyl11-((1R,2S)-2-((S)-2-((tert-butyldimethylsilyl)oxy)-2-(1-(2-((tert-butyl-
diphenylsilyl)oxy)ethyl)-2-methyl-1H-benzo[d]imidazol-5-yl)ethyl)cyclopropyl)-4,4,6,8-tetra
-methyl-5-oxo-7-((triisopropylsilyl) oxy) undecanoate (10)
Triethylamine (TEA) (103 µL, 0.742 mmol) was slowly added to a solution of olefin 10A (39 mg,
0.037 mmol) and NBSH (161 mg, 0.742 mmol) in DCM (2 mL) at rt, and the reaction mixture was stirred
overnight. As the reaction was not complete at this point, additional TEA (200 µL, 1.439 mmol) was
added over a period of 4 h. After an additional 20 h, more NBSH (50 mg, 0.23 mmol) and TEA (100 µL,
0.72 mmol) were added, and stirring was continued for 16 h. The solution was then washed with brine,
dried over MgSO4, and concentrated in vacuo. Purification of the residue by FC (Hex/EtOAc 2:1)
yielded 38.1 mg of saturated ester 10 (98%) as a mixture of isomers (see text).
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Rf = 0.81 (EtOAc/Hex 1:1). [α]
20
D = −20.6 (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.60
(1H, s), 7.23–7.43 (10H, m), 7.12 (1H, dd, J = 1.30, 8.35 Hz), 7.03 (1H, d, J = 8.35 Hz,), 4.77 (1H, dd,
J = 5.48, 7.32 Hz), 4.22 (2H, t, J = 5.59 Hz), 4.03 (1H, dd, J = 2.58, 6.10 Hz), 3.89 (2H, t, J = 5.59 Hz), 3.64
(3H, s), 3.11 (1H, q, J = 6.70 Hz), 2.54 (3H, s), 2.22 (2H, m), 1.84 (3H, m), 1.49 (1H, m), 1.21-1.45 (5H, m),
1.19 (3H, s), 1.10 (29H, m), 0.94 (3H, m), 0.93 (9H, s), 0.88 (9H, s), 0.49 (1H, m), 0.41 (1H, m), 0.13 (2H,
m), 0.03 (3H, s), −0.14 (3H, s). 13C NMR (100 MHz, CDCl3): δ = 217.94, 174.11, 152.16, 142.53, 140.11,
135.53, 134.45, 132.67, 129.94, 127.91, 120.39, 116.46, 108.78, 77.04, 75.96, 62.13, 51.73, 47.63, 46.71, 45.89,
42.78, 40.31, 34.82, 34.55, 32.35, 29.87, 27.91, 26.75, 26.07, 24.88, 24.80, 19.08, 19.03, 18.58, 18.55, 18.40,
15.93, 15.88, 15.78, 14.15, 13.53, 11.85, −4.36, −4.76. IR: ν = 2929, 2861, 2357, 1740, 1697, 1521, 1471,
1429, 1390, 1361, 1254, 1111, 1086, 1006, 883, 836, 776, 740, 703, 505 cm−1. HRMS (ESI): m/z calcd for
C62H100N2O6Si3 + H+: 1053.6962 [M + H+]; found 1053.6957.
(6R,7S,8S)-Methyl11-((1R,2S)-2-((S)-2-(1-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-2-methyl-1H
-benzo[d]imidazol-5-yl)-2-hydroxyethyl)cyclopropyl)-4,4,6,8-tetramethyl-5-oxo-7-((triisopropyl
-silyl)oxy)undecanoate (11)
Camphorsulfonic acid (CSA) (0.3 g, 1.291 mmol) was added to a solution of silyl ether 10 (0.38 g,
0.361 mmol) in DCM/MeOH 1:1 (16 mL). The solution was stirred overnight at rt and then neutralized
with sat. aq. NaHCO3. The aqueous layer was extracted with DCM, and the combined organic layers
were dried over MgSO4 and concentrated in vacuo. Purification of the residue by FC (Hex/EtOAc 9:1)
yielded 0.34 g of partially protected seco acid 11 (quant) as a mixture of isomers (see text).
Rf = 0.67 (EtOAc/Hex 9:1). [α]
20
D = −14.7 (c = 1.1 in CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.65
(1H, s), 7.24–7.42 (10H, m), 7.17 (1H, dd, J = 1.41, 8.34 Hz), 7.04 (1H, d, J = 8.34 Hz), 4.84 (1H, t,
J = 6.55 Hz), 4.22 (2H, t, J = 5.66 Hz), 4.03 (1H, dd, J = 2.53, 6.10 Hz,),3.89 (2H, t, J = 5.66 Hz), 3.64
(3H, s), 3.12 (1H, q, J = 6.62 Hz), 2.55 (3H, s), 2.22 (2H, m), 1.83 (3H, m), 1.61 (1H, m), 1.48 (1H, m),
1.28 (3H, m), 1.19 (3H, s), 1.09 (30H, m), 0.94 (9H, s,), 0.92 (3H, m), 0.48 (2H, m), 0.17 ppm (2H, m). 13C
NMR (100 MHz, CDCl3): δ = 217.96, 174.14, 152.57, 142.74, 138.92, 135.53, 134.80, 132.65, 129.98, 127.91,
120.31, 116.60, 109.25, 77.05, 75.53, 62.02, 51.76, 47.62, 45.88, 44.26, 42.81, 40.27, 34.74, 34.54, 32.34, 29.86,
27.94, 26.77, 24.88, 24.79, 19.06, 19.00, 18.58, 18.55, 15.92, 15.76, 15.64, 14.13, 13.54, 11.51. IR: ν = 3229,
2930, 2865, 2356, 1739, 1696, 1521, 1462, 1429, 1403, 1390, 1111, 1087, 1007, 883, 740, 703, 504 cm−1.
HRMS (ESI): m/z calcd for C56H86N2O6Si2 + H+: 939.6097 [M + H+]; found 939.6093.
(6R,7S,8S)-11-((1R,2S)-2-((S)-2-(1-(2-((tert-Butyldiphenylsilyl)oxy)ethyl)-2-methyl-1H-benzo[d]
imidazol-5-yl)-2-hydroxyethyl)cyclopropyl)-4,4,6,8-tetramethyl-5-oxo-7((triisopropylsilyl)oxy)
undecanoic acid (11A)
Lithium hydroxide monohydrate (223.1 mg, 5.555 mmol) was added to a solution of methyl ester
11 (1.04 g, 1.111 mmol) in t-BuOH/H2O 4:1 (30 mL). The solution was stirred for 2.5 h at rt. Water
and 1 M HCI (to pH 5) were then added, and the solution was extracted with DCM. The combined
organic extracts were dried over MgSO4 and evaporated in vacuo to furnish obtain 1.000 g of crude
acid 11A (98%) as a white powder. This material was used in the next step without further purification.
Rf = 0.15 (EtOAc/MeOH 95:5). [α]
20
D = +16.4 (c = 0.7 in CHCl3).
1H NMR (400 MHz, CDCl3): δ = 7.71
(1H, s), 7.25–7.43 (10H, m), 7.35 (1H, m), 7.14 (1H, d, J = 8.46 Hz), 4.85 (1H, dd, J = 4.43, 10.00 Hz), 4.22
(2H, m), 4.05 (1H, dd, J = 2.98, 4.59 Hz), 3.89 (2H, t, J = 5.60 Hz), 3.18 (1H, m), 2.56 (3H, s), 2.21–2.36
(2H, m), 2.07 (1H, m), 1.93 (2H, m), 1.67 (1H, m), 1.50 (3H, m), 1.31 (3H, s), 1.25 (1H, m), 1.24 (1H,
m), 1.06–1.15 (29H, m), 0.95 (3H, m), 0.94 (9H, s), 0.53 (1H, m), 0.10–0.23 (2H, m), −0.04 (1H, m). 13C
NMR (100 MHz, CDCl3): δ = 219.00, 176.43, 152.33, 139.77, 139.20, 135.51, 134.03, 132.53, 130.09, 127.98,
119.90, 117.33, 110.31, 75.76, 75.75, 61.93, 47.58, 45.88, 44.04, 41.65, 40.94, 35.32, 34.25, 33.60, 30.46, 27.96,
26.78, 24.81, 24.36, 19.08, 18.92, 18.52, 18.47, 16.05, 15.00, 13.34, 13.22, 13.13, 11.50. IR: ν = 2960, 2930,
2865, 2358, 2338, 1698, 1520, 1472, 1428, 1407, 1390, 1362, 1111, 1088, 883, 773, 741, 703 cm−1. HRMS
(ESI): m/z calcd for C55H84N2O6Si2 + H+: 925.5941 [M + H+]; found 925.5937.
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(1S,3S,10R,11S,12S,16R)-3-(1-(2-((tert-Butyldiphenylsilyl)oxy)ethyl)-2-methyl-1H-benzo[d]
imidazol-5-yl)-8,8,10,12-tetramethyl-11-((triisopropylsilyl)oxy)-4-oxabicyclo[14.1.0]
heptadecane-5,9-dione (12)
A solution of acid 11A (988 mg, 1.067 mmol) in toluene (20 mL) was slowly added to a solution of
TEA (297 µL, 1.135 mmol), 2,4,6 trichlorobenzoyl chloride (184 µL, 1.174 mmol) and DMAP (170 mg,
1.388 mmol) in toluene (500 mL) at rt. The mixture was stirred for 2 h and the reaction was then
quenched with sat. aq. NaHCO3. The solution was extracted with EtOAc, and the combined
extracts were dried over MgSO4 and then concentrated in vacuo. Purification of the residue by
FC (Hex/EtOAc/MeOH 1:1:0.01) followed by preparative RP-HPLC gave 493 mg of slightly impure
macrolactone 12 (51%). Preparative RP-HPLC: H2O with 0.1% TFA (A)/CH3CN (B). 10% B to 80%
over 20 min, retention time: 8.54 min.
Rf = 0.35 (EtOAc: Hex 1:1). [α]
20
D = −15.7 (c = 1.0 in CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.82
(s, 1H), 7.35 (m, 6H), 7.25 (m, 6H), 5.96 (d, J = 10.1 Hz, 1H), 4.34 (d, J = 5.2 Hz, 2H), 4.19 (dd, J = 7.3,
2.2 Hz, 1H), 4.00 (t, J = 4.5 Hz, 2H), 3.24 (p, J = 7.0 Hz, 1H), 2.79 (s, 3H), 2.35 (tdd, J = 27.4, 16.2, 5.2 Hz,
2H), 2.10 (dd, J = 14.5, 3.2 Hz, 1H), 1.95 (pd, J = 13.8, 5.3 Hz, 2H), 1.57–1.41 (m, 4H), 1.39 (s, 3H),
1.37–1.30 (m, 2H), 1.25 (s, 4H), 1.17 (d, J = 7.0 Hz, 4H), 1.12 (s, 18H), 1.06 (s, 4H), 0.98 (d, J = 6.8 Hz,
3H), 0.92 (s, 9H), 0.79–0.70 (m, 1H), 0.57 (dt, J = 12.9, 4.4 Hz, 1H), 0.22 ppm (tt, J = 9.4, 4.7 Hz, 2H). 13C
NMR (101 MHz, CDCl3): δ = 218.62, 172.29, 151.22, 141.20, 135.31, 131.80, 131.56, 131.32, 130.44, 128.11,
124.67, 112.70, 111.30, 77.48, 76.79, 61.11, 47.35, 46.98, 43.58, 41.96, 39.70, 34.89, 34.47, 30.93, 26.79, 26.51,
25.15, 23.98, 18.99, 18.62, 18.58, 18.04, 17.02, 16.75, 16.00, 13.58, 11.80. IR: ν = 2932, 2865, 2359, 2338,
1731, 1695, 1521, 1463, 1429, 1390, 1255, 1111, 1088, 999, 981, 939, 883, 823, 754, 703, 677, 504 cm−1.
HRMS (ESI): m/z calcd for C55H82N2O5Si2 + H+: 907.5835 [M + H+]; found 907.5837.
(1S,3S,10R,11S,12S,16R)-11-Hydroxy-3-(1-(2-hydroxyethyl)-2-methyl-1H-benzo[d]imidazol-5
-yl)-8,8,10,12-tetramethyl-4-oxabicyclo[14.1.0] heptadecane-5,9-dione (1)
Fully protected macrolactone 12 (40 mg, 0.044 mmol) was dissolved in THF (3 mL) and
HF·pyridine (2 mL) was added. The solution was stirred overnight and the reaction then slowly
quenched with aq. sat. NaHCO3. The solution was extracted with EtOAc and the combined organic
phases were washed with aq. sat. NaHCO3, dried over MgSO4 and concentrated in vacuo. Purification
of the residue by FC (CHCl3/MeOH/H2O/AcOH 85:13:1.5:0.5) was followed by preparative RP-HPLC
purification. RP-HPLC: Injection of a solution of 1 in MeOH and elution with 0.1% TFA in H2O
(A)/MeCN (B); 30% B for 2 min, then gradient to 60% B over 6 min, and then gradient to 90% B over 3
min. Preparative runs: 30% B for 2 min and then to 90% B over 10 min; retention time 4.67 min (prep).
An amount of 9.11 mg of pure 1 was isolated (33%) with further mixed fractions.
Rf = 0.37 (CHCl3/MeOH/H2O/AcOH 85:13:1.5:0.5). [α]
20
D = −15.1 (c = 0.5 in MeOH). 1H NMR
(500 MHz, MeOD): δ = 7.79 (d, J = 8.7 Hz, 1H), 7.69 (s, 1H), 7.54 (dd, J = 8.6, 0.7 Hz, 1H), 6.05 (dd,
J = 11.0, 1.0 Hz, 1H), 4.53 (t, J = 5.1 Hz, 2H), 3.97–3.93 (m, 2H), 3.70 (dd, J = 9.9, 1.4 Hz, 1H), 3.29 (d,
J = 6.7 Hz, 1H), 2.87 (s, 3H), 2.42–2.32 (m, 1H), 2.24 (dd, J = 8.6, 6.9 Hz, 1H), 2.21–2.12 (m, 1H), 2.03–1.94
(m, 1H), 1.87 (td, J = 14.4, 5.2 Hz, 1H), 1.71 (dd, J = 12.8, 5.2 Hz, 1H), 1.57 (d, J = 9.4 Hz, 1H), 1.48–1.42
(m, 2H), 1.35–1.24 (m, 3H), 1.20 (d, J = 6.7 Hz, 3H), 1.09 (dd, J = 16.0, 6.9 Hz, 1H), 1.02 (s, 3H), 0.99 (d,
J = 6.6 Hz, 3H), 0.91–0.86 (m, 1H), 0.67–0.61 (m, 1H), 0.27–0.20 (m, 2H). 13C NMR (100 MHz, CDCl3):
δ = 219.48, 172.13, 152.26, 140.88, 131.37, 131.17, 124.47, 112.29, 111.41, 76.71, 75.83, 59.56, 47.82, 47.55,
42.31, 41.63, 36.04, 34.37, 32.02, 30.94, 29.53, 25.54, 25.35, 22.78, 22.39, 18.62, 17.23, 16.98, 14.96, 12.03. IR:
ν = 3414, 2966, 2934, 2878, 2363, 1729, 1674, 1460, 1426, 1200, 1175, 1138, 975, 798, 722 cm−1; HRMS
(ESI): m/z calcd for C30H44N2O5 + H+: 513.3323 [M + H+]; found 513.3323.
(1S,3S,10R,11S,12S,16R)-3-(1-(2-Hydroxyethyl)-2-methyl-1H-benzo[d]imidazol-5-yl)-8,8,10,12
-tetramethyl-11-((triisopropylsilyl)oxy)-4-oxabicyclo[14.1.0] heptadecane-5,9-dione (13)
A solution of dry TASF (28.2 mg, 0.102 mmol) in DMF (90 µL) was added to a solution of dry
12 (93 mg, 0.102 mmol, HPLC purified) in DMF (5 mL) at 0 ◦C, and the solution was stirred for 2 h.
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Phosphate buffer pH 7 was then added, and the solution was extracted with DCM, dried over MgSO4
and concentrated in vacuo. Purification of the residue by FC (EtOAc/MeOH 100:1) yielded 70 mg
(quant) of alcohol 13 as a colorless oil.
Rf = 0.35 (EtOAc/MeOH 95:5). [α]
20
D = −21.3 (c = 0.7 in CHCl3). 1H NMR (400 MHz, CDCl3):
δ = 7.51 (1H, s), 7.21 (1H, d, J = 8.22 Hz), 7.13 (1H, dd, J = 1.39, 8.33 Hz), 5.98 (1H, d, J = 10.20 Hz), 4.21
(2H, t, J = 5.17 Hz), 4.16 (1H, dd, J = 2.14, 7.10 Hz), 3.98 (2H, t, J = 5.17 Hz), 3.23 (1H, q, J = 7.00 Hz),
2.47 (3H, s), 2.82 (2H, m), 2.07 (1H, m), 1.92 (2H, m), 1.48 (3H, m), 1.35 (3H, s), 1.26 (5H, m), 1.17 (3H, d,
J = 7.04 Hz), 1.11 (21H, s), 1.04 (3H, s), 0.98 (3H, d, J = 6.84 Hz), 0.71 (1H, m), 0.58 (1H, m), 0.20 (2H, m).
13C NMR (100 MHz, CDCl3): δ = 218.28, 172.26, 153.05, 142.16, 136.05, 134.68, 120.90, 115.93, 109.27,
77.65, 77.38, 60.78, 47.43, 46.54, 43.52, 42.17, 39.69, 34.86, 34.50, 31.06, 26.59, 25.49, 23.83, 18.68, 18.68,
18.61, 18.05, 17.27, 16.71, 16.06, 13.91, 13.57, 11.41. IR: ν = 3197, 2962, 2942, 2866, 2356, 2338, 1731, 1696,
1520, 1465, 1406, 1389, 1254, 1122, 1067, 1041, 999, 982, 883, 756, 677cm−1; HRMS (ESI): m/z calcd for
C39H64N2O5Si + H+: 669.4657 [M + H+]; found 669.4649.
S-(2-(5-((1S,3S,10R,11S,12S,16R)-11-Hydroxy-8,8,10,12-tetramethyl-5,9-dioxo-4-oxabicyclo[14.1.0]
heptadecan-3-yl)-2-methyl-1H-benzo[d]imidazol-1-yl)ethyl) ethanethioate (14)
DEAD (35 µL, 0.219 mmol) was added to a solution of PPh3 (57.6 mg, 0.219 mmol) in Et2O (4 mL)
at 0 ◦C, and the mixture was stirred for 1 h at that temperature. Thioacetic acid (17 µL, 0.241) was then
added followed by slow addition of a solution of 13 (70 mg, 0.104 mmol) in Et2O (5 mL). The cooling
bath was removed, and the solution was stirred at rt for 2.5 h. It was then washed with brine, and
the aqueous solution was back-extracted with EtOAc. The combined organic extracts were dried over
MgSO4 and concentrated in vacuo. Purification of the residue by FC (EtOAc/MeOH 100:1) gave 130 mg
of protected thioacetate contaminated with triphenylphosphine oxide; 5 mg of 13 were recovered. The
protected thioacetate was dissolved in THF (5 mL) and a total of 5 mL of pyridine and 9 mL of HF py
were added in portions over a period of 53 h. NaHCO3 was then carefully added to the mixture to
reach pH 7–8, and the solution was extracted with EtOAc. The combined organic extracts were dried
over MgSO4 and concentrated in vacuo. Purification of the residue by FC (CHCl3/MeOH/H2O/AcOH
90:10:1:0.5 and CHCl3/MeOH/AcOH 95:4.5:0.5) yielded 52 mg (87% over 2 steps) of thioacetate 14 as
a colorless oil. Ten milligrams of this material were purified by preparative RP-HPLC: Injection of a
solution of 1 in MeOH and elution with 0.1% TFA in H2O (A)/CH3CN (B); 30% B for 2 min, then to
60% B over 6 min, and then to 90% B over 3 min. Preparative HPLC: 30% B for 2 min and then to 70%
over 10 min. Retention time 6.60 (prep). An amount of 2.42 mg of pure 14 was recovered after HPLC
(22% yield based on 13).
Rf = 0.07 (CHCl3/MeOH/AcOH 95:4.5:0.5). [α]
20
D = −27.1 (c = 0.9 in CHCl3). 1H NMR (400 MHz,
CDCl3): δ = 7.62 (1H, s), 7.36 (1H, d, J = 8.26 Hz), 7.20 (1H, dd, J = 1.39, 8.26 Hz), 6.00 (1H, dd, J = 1.62,
10.19Hz), 4.22 (2H, m), 3.78 (1H, dd, J = 3.09, 6.72 Hz), 3.29 (1H, q, J = 6.72 Hz), 3.16 (2H, m), 2.65 (3H,
s), 2.38 (3H, s), 2.17–2.34 (2H, m), 2.11 (1H, m), 1.87–2.02 (2H, m), 1.54 (5H, m), 1.34 (3H, s), 1.25 (2H,
m), 1.18 (3H, d, J = 6.79 Hz), 1.02 (3H, s), 1.00 (3H, d, J = 6.79 Hz), 0.89 (1H, m), 0.64 (1H, m), 0.56 (1H,
m), 0.18 ppm (2H, m). 13C NMR (100 MHz, CDCl3): δ = 219.18, 195.28, 172.02, 152.20, 142.01, 136.43,
134.11, 121.33, 116.05, 109.1, 77.51, 76.07, 47.88, 43.16, 42.32, 41.93, 36.11, 34.44, 34.41, 31.11, 30.79, 29.86,
28.24, 25.69, 25.55, 22.26, 18.53, 17.33, 17.28, 15.21, 13.63, 11.01. IR: ν = 3267, 2962, 2930, 2856, 2363, 1725,
1691, 1521, 1458, 1402, 1252, 1133, 1039, 975, 754, 623 cm−1; HRMS (ESI): m/z calcd for C32H46N2O5S +
H+: 571.3200 [M + H+]; found 571.3195.
(1S,3S,10R,11S,12S,16R)-11-Hydroxy-8,8,10,12-tetramethyl-3-(2-methyl-1-(2-(pyridin-2-
yldisulfanyl)ethyl)-1H-benzo[d]imidazol-5-yl)-4-oxabicyclo[14.1.0] heptadecane-5,9-dione (15)
K2CO3 (5 mg) was added to a solution of 14 (11 mg, 0.019 mmol) and 2,2′-dipyridyl disulfide
(5.1 mg, 0.023 mmol) in dry MeOH (2 mL), and the mixture was stirred at rt for 30 min. Brine was added
and the solution was extracted with EtOAc. The combined organic extracts were dried over MgSO4
and concentrated. Purification of the residue by FC yielded 9.7 mg (79%) of activated disulfide 15.
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Rf = 0.76 (EtOAc/MeOH 9:1). [α]
20
D = −45.3 (c = 0.4 in CHCl3). 1H NMR (400 MHz, CDCl3):
δ = 8.50 (1H, dq, J = 0.90, 4.02 Hz) 7.60 (3H, m), 7.22 (1H, d, J = 8.21 Hz), 7.14 (2H, m), 4.98 (1H, dd,
J = 1.72, 10.18 Hz), 4.46 (2H, t, J = 7.31 Hz), 3.77 (1H, dd, J = 2.95, 6.66 Hz), 3.28 (1H, q, J = 6.76 Hz),
3.12 (2H, t, J = 7.33 Hz), 2.60 (3H, s), 2.13–2.38 (2H, m,), 2.07 (1H, m), 1.80–2.01 (2H, m), 1.54 (5H, m),
1.33 (3H, s), 1.27 (2H, m), 1.18 (3H, d, J = 6.76 Hz), 1.02 (3H, s), 1.00 (3H, d, J = 6.85 Hz), 0.87 (1H, m),
0.56–0.64 (2H, m), 0.18 (2H, m). 13C NMR (100 MHz, CDCl3): δ = 219.13, 171.99, 158.78, 152.24, 150.30,
142.73, 137.36, 136.23, 134.38, 121.56, 121.14, 120.68, 116.28, 108.83, 77.57, 76.07, 47.89, 42.94, 42.32, 42.01,
37.12, 36.13, 34.47, 34.43, 31.13, 29.90, 25.75, 25.59, 22.29, 18.56, 17.38, 17.28, 15.19, 14.26, 11.06. IR:
ν = 3269, 2926, 2855, 2017, 1727, 1690, 1574, 1521, 1447, 1418, 1401, 1250, 975, 760 cm−1; HRMS (ESI):
m/z calcd for C35H47N3O4S2 + H+: 638.3081 [M + H+]; found 638.3075.
(S)-2-((S)-1-((6R,9S,12S,15S,18S,24S,27S)-12-((1H-imidazol-4-yl)methyl)-15-((1H-indol-3-yl)
methyl)-6-amino-1-(5-((1S,3S,10R,11S,12S,16R)-11-hydroxy-8,8,10,12-tetramethyl-5,9-dioxo-4-
oxabicyclo[14.1.0]heptadecan-3-yl)-2-methyl-1H-benzo[d]imidazol-1-yl)-9,18,24-tris(4-hydroxy
-benzyl)-27-((R)-1-hydroxyethyl)-7,10,13,16,19,22,25-heptaoxo-3,4-dithia-8,11,14,17,20,23,26
-heptaazaoctacosan-28-oyl)pyrrolidine-2-carboxamido)-N1-((S)-4-amino-1-(((S)-1-(((2S,3S)-
1-amino-3-methyl-1-oxopentan-2-yl)amino)-3-methyl-1-oxobutan
-2-yl)amino)-1,4-dioxobutan-2-yl)pentanediamide (4)
Cys-GE11 (11 mg, 0.0067 mmol) and 15 (4.3 mg, 0.0067 mmol) were dissolved in MeOH, and
the solution was stirred at rt for 2 h. Evaporation of the solvent and purification of the residue by
preparative HPLC yielded 2.45 mg (15%) of conjugate 4. Analytical RP-HPLC (C18): H2O with 0.1%
TFA (A)/H2O/CH3CN 8/2 with 0.05% TFA (B); gradient from 5% B to 80% B over 30 min. Preparative
RP-HPLC: Gradient from 5% B to 70% B over 30 min. [α]20D = −1.5 (c = 0.2 in MeOH). IR: ν = 3853, 3821,
3751, 3735, 3710, 3690, 3676, 3670, 3649, 3629, 3587, 3567, 2361, 2334, 1684, 1559, 1540, 1507, 1457, 1208,
1186, 1138, 801, 725 cm−1; HRMS (ESI): m/z calcd for C108H145N21O23S2 + H+: 2169.0341 [M + H+];
found 2169.0355 (Figure 4).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 14 of 18 
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time points, and the reaction was quenched with one volume of 10% metaphosphoric acid, giving a 
pH of 1 approximately. Fifty microliters of this solution were analyzed by analytical RP-HPLC. The 
same protocol was used for cleavage under endosome-like conditions, except that the glutathione 
solution was prepared in a 100 mM acetate buffer at pH 4.8, and the same buffer was also used to 
Figure 4. Analytical RP-HPLC trace of 4 after preparative RP-HPLC.
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Dimer of (1S,3S,10R,11S,12S,16R)-11-hydroxy-3-(1-(2-mercaptoethyl)-2-methyl-1H-benzo[d]
imidazol-5-yl)-8,8,10,12-tetramethyl-4-oxabicyclo[14.1.0]heptadecane-5,9-dione (16)
K2CO3 (5 mg) was added to a solution of 14 (13 mg, 0.023 mmol) in dry MeOH (2 mL), and the
mixture was stirred at rt for 20 min. Brine was added and the solution was extracted with EtOAc.
The combined organic extracts were dried over MgSO4 and concentrated. The crude residue was
purified by preparative HPLC. Although care was taken throughout the purification process to exclude
air as much as possible, the material recovered after lyophilization contained disulfide 16 as the major
component. Repurification of this material gave 3.51 mg (24%) of pure disulfide 16. Preparative
RP-HPLC: H2O with 0.1% TFA/CH3CN; 30% B for 2 min and then to 90% B over 10 min. Retention
time 5.44 min/6.21 min for monomer/dimer (prep).
Rf = 0.76 (EtOAc/MeOH 9:1). [α]
20
D =−3.3 (c = 0.1 in MeOH). 1H NMR (500 MHz, MeOD): δ = 7.82
(d, J = 8.6 Hz, 2H), 7.70 (s, 2H), 7.57 (dd, J = 8.7, 1.3 Hz, 2H), 6.04 (d, J = 10.5 Hz, 2H), 4.73 (t, J = 6.5 Hz,
4H), 3.70 (dd, J = 9.7, 0.9 Hz, 2H), 3.26 (t, J = 6.3 Hz, 4H), 2.88 (s, 6H), 2.35 (ddd, J = 16.2, 12.9, 4.7 Hz,
2H), 2.22 (d, J = 14.5 Hz, 2H), 2.19–2.11 (m, 2H), 1.91 (dtd, J = 53.2, 13.6, 4.7 Hz, 5H), 1.75–1.63 (m, 2H),
1.60–1.51 (m, 3H), 1.48–1.41 (m, 4H), 1.40 (s, 6H), 1.30–1.23 (m, 3H), 1.19 (d, J = 6.7 Hz, 6H), 1.13–1.04
(m, 3H), 1.00 (s, 6H), 0.98 (d, J = 6.6 Hz, 6H), 0.92–0.82 (m, 2H), 0.63 (tt, J = 12.7, 6.4 Hz, 2H), 0.26–0.19
(m, 4H). 13C NMR (126 MHz, MeOD) δ = 218.32, 172.15, 152.13, 140.96, 131.64, 123.91, 119.94, 112.34,
111.38, 77.27, 77.16, 47.02, 43.94, 43.56, 41.44, 35.60, 35.13, 34.29, 34.01, 30.29, 28.02, 25.30, 24.68, 21.72,
18.12, 17.79, 17.22, 15.98, 10.82, 9.44. IR: ν = 2927, 2852, 2363, 2343, 2018, 1715, 1684, 1199, 1138, 974, 725
cm−1; HRMS (ESI): m/z calcd for C60H86N4O8S2 + H+: 1055.5960 [M + H+]; found 1055.5958.
3.2. Glutathione Cleavage Assay
For cytoplasm-like conditions, 100 µL of a 173 µM solution of conjugate 4 in degassed 100 mM
phosphate buffer pH 7.4 were diluted with 400 µL of a degassed phosphate buffer and 500 µL of
20 mM glutathione in 100 mM phosphate buffer pH 7.4. Aliquots of 80 µL were removed at predefined
time points, and the reaction was quenched with one volume of 10% metaphosphoric acid, giving a pH
of 1 approximately. Fifty microliters of this solution were analyzed by analytical RP-HPLC. The same
protocol was used for cleavage under endosome-like conditions, except that the glutathione solution
was prepared in a 100 mM acetate buffer at pH 4.8, and the same buffer was also used to dilute the
conjugate solution in a 100 mM phosphate buffer at pH 7.4. The final pH of the cleavage solution
was 4.9.
Analytical RP-HPLC: H2O with 0.1% TFA (A)/acetonitrile/water 8/2 with 0.05% TFA (B). Linear
gradient from 5% B to 80% B over 30 min. The percentage of remaining conjugate in the solutions was
plotted against time (Figure 3). Analysis of the cleavage solutions by LC/MS provided information of
the fractions of the various components in the redox mixture. As an example, Figure S2 shows the
product distribution after 5 min of reaction time under endosome-like conditions.
3.3. Determination of Microtubule Binding Constants
Purified calf-brain tubulin and chemicals were obtained as previously described [50]. Stabilized,
moderately crosslinked microtubules were prepared as reported in [42]. Binding constants of
azathilones to stabilized microtubules were measured as previously described by Buey et al. [41].
For details of the experimental procedures and Flutax-2 displacement curves cf. Section SI.3 of the
Supplementary Materials.
3.4. Antiproliferative Activity
Experiments were performed in RPMI (SW480 cells) or DMEM (HEK293 and A431 cells) medium
(Gibco) supplemented with 2 mM glutamine, 10% fetal bovine serum, 100 IU/mL penicillin, 100 µg/mL
streptomycin, and 1 µg/mL amphotericin B (all from Sigma) at 37 ◦C and 5% CO2. Cells were seeded
into 96-well microtiter plates and compounds were added in DMSO in serial dilutions in triplicate.
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The final DMSO (dimethylsulfoxide) concentration was 0.1%. After 72 h, a WST-1 reagent [43]
was added and the absorption was measured at 450 nm with a plate reader after 30 min to 4 h.
The percentage of viable cells was calculated based on vehicle-treated cells and was plotted in
GraphPadPrism. At least three independent experiments were performed.
A431 cells were obtained from CLS. The other cell lines were available in the laboratory. WST-1
was purchased from Roche.
For inhibition curves cf. Section SI.5 of the Supplementary Materials.
4. Conclusions
We have successfully prepared a disulfide-linked conjugate between a novel epothilone analog
and the (purported) EGFR-binding peptide GE11, and we have determined its microtubule-binding
affinity and its in vitro antiproliferative activity against EGFR-overexpressing cells and cells being
devoid of EGFR. While the conjugate had been designed to specifically target EGFR-overexpressing
cells, its in vitro antiproliferative activity was found to be independent of EGFR expression status, at
least for the limited number of cell lines evaluated. While our study has been limited in scope, in
combination with other data in the literature, our findings could suggest that GE11 does not represent
an effective targeting moiety for EGFR-overexpressing tumor cells, and even less so in combination
with a disulfide linker (contrary to our original working hypothesis).
Independent of the uncertainties surrounding the activity of the specific epothilone conjugate 4
that we have investigated in this study, our work does demonstrate that the new epothilone analog
1 can serve as highly active template for the construction of targeted prodrugs. The compound
exhibits nM antiproliferative activity against a variety of cell lines and offers a readily accessible,
sterically unencumbered primary hydroxyl group for chemical manipulation; the requisite partially
protected precursor for these manipulations (i.e., intermediate 13) can be prepared on a scale that
allows the production of reasonable amounts of prodrugs for subsequent biochemical, cell biological,
and pharmacological studies. The preparation of such prodrugs will be the subject of future studies in
our laboratory.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/5/1113/
s1.
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